Steve Dawe
About Steve Dawe
Steve Dawe is the Senior Director of Project Management and Clinical Business Operations at Adaptimmune, where he has worked since 2020. With a background in leading global drug development programs, he has held significant roles at Bayer and Novartis prior to his current position.
Work at Adaptimmune
Steve Dawe has been serving as the Senior Director of Project Management and Clinical Business Operations at Adaptimmune since 2020. In this role, he oversees project management and operational strategies to support clinical development initiatives. Prior to this position, he held the role of Director of Project Management at Adaptimmune from 2018 to 2020. His tenure at Adaptimmune has been marked by a focus on advancing the company's clinical programs and ensuring effective project execution in the biopharmaceutical sector.
Education and Expertise
Steve Dawe studied at the University of Warwick, where he gained foundational knowledge that supports his extensive career in the pharmaceutical industry. He possesses significant expertise in leading global drug development programs, spanning from early research phases to successful product registration. His educational background complements his professional experience, enabling him to navigate complex clinical and regulatory landscapes effectively.
Background
Before joining Adaptimmune, Steve Dawe worked at Bayer as a Global Program Head from 2013 to 2018, where he managed international drug development projects. His earlier experience includes an eight-year tenure at Novartis as a Global Program Head from 2005 to 2013. Throughout his career, he has developed a strong understanding of the pharmaceutical industry, particularly in managing multidisciplinary teams and regulatory submissions across various global markets.
Achievements
Steve Dawe has demonstrated a proven ability to lead simultaneous regulatory submissions in the US, EU, and Japan. His leadership has been instrumental in navigating complex international regulatory environments, showcasing his capability in managing diverse teams of clinical, regulatory, and commercial experts. His contributions have supported the design and delivery of innovative global development programs across a wide range of clinical indications.